Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics

[at noodls] – SAN DIEGO, CA — (MARKETWIRE) — 03/06/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has signed a collaboration and license agreement to develop cancer … more

View todays social media effects on LPTN

View the latest stocks trending across Twitter. Click to view dashboard

See who Lpath is hiring next, click here to view